Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

This study has been completed.
Information provided by (Responsible Party):
Keryx / AOI Pharmaceuticals, Inc. Identifier:
First received: November 15, 2006
Last updated: February 7, 2012
Last verified: February 2012